T
26.35
-0.19 (-0.72%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Tvardi Therapeutics, Inc. | - | - |
AIStockmoo 评分
0.0
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.00 |
|
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Lri Investments, Llc | 31 Mar 2025 | 83 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 65.00 (Oppenheimer, 146.68%) | 购买 |
| 中 | 52.00 (97.34%) | |
| 低 | 39.00 (Jones Trading, 48.01%) | 购买 |
| 平均值 | 52.00 (97.34%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 26.87 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Oppenheimer | 21 May 2025 | 65.00 (146.68%) | 购买 | 32.72 |
| Jones Trading | 28 Apr 2025 | 39.00 (48.01%) | 购买 | 21.02 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合